Document:

EX-10.17

 Exhibit 10.17 
 December 2, 2011 
 Louis J. Arcudi, III 

4 Whitney Road 
 Hopedale, MA 01747 

Dear Lou: 
 This letter amends and restates the
employment letter dated August 1, 2011 between you and Idera Pharmaceuticals, Inc. (the “Company”), as amended (the “Prior Agreement”). Effective upon the date of this Agreement (the “Effective Date”), your
continued employment with the Company shall be on the terms set forth in this Agreement and the Prior Agreement shall be terminated and of no further force or effect. 
  

	1.	Employment. You will be employed to serve on a full time basis as Chief Financial Officer and Senior Vice President, Operations of the Company, reporting
solely to the Chief Executive Officer and performing such duties as are customarily assigned to a chief financial officer or senior vice president, operations, plus such other duties as may from time to time be assigned to you by the Chief Executive
Officer. You agree to devote your full business time, best efforts, skill, knowledge, attention and energies to the advancement of the Company’s business and interests and to the performance of your duties and responsibilities as an employee of
the Company. 

  

	2.	 Base Salary and Bonus. Your annual base salary shall be $315,000 per year and shall be payable to you at periodic intervals in accordance
with the Company’s payroll practices for salaried employees. Such base salary may be adjusted from time to time in accordance with normal business practices and in the sole discretion of the Company. You shall also be eligible to receive, for
each fiscal year of the Company ending during your employment with the Company, an annual bonus, whether pursuant to a formal bonus or incentive plan or program of the Company or otherwise. Such bonus, if any, will be approved by the Board of
Directors or the Compensation Committee of the Board of Directors (together, the “Board”) in its sole discretion and will be based on both individual and Company performance objectives as developed and determined by the Company in its sole
discretion. Any bonus earned by you and approved by the Board under this Section 2 shall be paid to you no later than March 15th of the calendar year following the calendar year in which such bonus is earned and approved by the Board under this
Section 2. All salary, bonus and other compensation payable to you pursuant to this Agreement shall be subject to applicable withholding taxes. 

  

	3.	 Benefit Programs. You may participate in any and all benefit programs that the Company may establish and make available to its employees
from time to time, provided you are eligible under (and subject to all provisions of) the plan documents governing those programs. Such benefits may include medical, dental and retirement plans. Any benefits

	 	
made available by the Company, and the rules, terms and conditions for participation in such benefit plans, may be changed by the Company at any time and from time to time without advance notice.

  

	4.	Reimbursement of Expenses. The Company shall reimburse you, in accordance with the Company’s expense reimbursement policy, for all reasonable travel,
entertainment and other expenses incurred or paid by you in connection with, or related to, the performance of your duties, responsibilities or services under this Agreement, upon presentation by you of appropriate documentation, expense statements,
vouchers and/or such other supporting information as the Company may request and in accordance with Section 10(e) below. 

  

	5.	Termination of Employment Period. Your employment by the Company pursuant to this Agreement shall terminate upon the occurrence of any of the following:

 (a)        At the election of the Company, for Cause (as defined below),
immediately upon written notice by the Company to you, which notice shall identify the Cause upon which the termination is based. 
 (b)        Upon your death or disability. As used in this Agreement, the term “disability” shall mean inability by you, due to a physical or mental
disability, for a period of 90 days, whether or not consecutive, during any 360-day period to perform the services contemplated under this Agreement, with or without reasonable accommodation as that term is defined under state or federal law. A
determination of disability shall be made by a physician satisfactory to both you and the Company, provided that if you and the Company do not agree on a physician, you and the Company shall each select a physician and these two
together shall select a third physician, whose determination as to disability shall be binding on all parties; 

(c)        At the election of either party, upon not less than fifteen days’ prior written
notice of termination. 
  

	6.	Effect of Termination. 

 (a)        In the event your employment is terminated pursuant to Section 5(a), Section 5(b) or Section 5(c), the Company shall pay to you the
compensation and benefits otherwise payable you under Section 2 through the last day of your actual employment by the Company. 
 (b)        In the event that the Company terminates your employment with the Company at any time without Cause pursuant to Section 5(c), then, subject to
Section 6(e), the Company shall continue to pay you your then current base salary for a period of twelve (12) months, payable in accordance with and at the times contemplated by the Company’s then current payroll practices.

 (c)        Notwithstanding Section 6(b) above, and in lieu of any payment owed
under Section 6(b), if any, in the event that the Company terminates you 

  
 - 2 -

 
without Cause or you resign from employment with the Company for Good Reason upon a Change in Control (as defined below) or within the twelve (12) month period following the Change in
Control, then, subject to Section 6(e), the Company shall continue to pay you your then current base salary for a twelve-month period, payable in accordance with and at the times contemplated by the Company’s then current payroll
practices. 
 (d)        Following a termination of your employment entitling you to
severance payments under Section 6(b) or Section 6(c), and subject to Section 6(e), if you are eligible for and elect to continue receiving group medical and/or dental insurance under the continuation coverage rules known as COBRA,
the Company will pay the share of the premium for such coverage that it pays for active and similarly-situated employees who receive the same type of coverage (single, family, or other) until the earlier of (i) the end of the period for which
the Company is paying you your then current base salary pursuant to Section 6(b) or Section 6(c) above (as applicable, the “Severance Period”) or (ii) the date your COBRA continuation coverage expires. 

(e)        Notwithstanding anything in this Section 6 to the contrary,
the Company’s obligations to make severance payments and provide benefits to you pursuant to this Section 6 shall be contingent upon your execution of a separation and release agreement (the “Release Agreement”) in a form
reasonably acceptable to the Company which Release Agreement must become irrevocable within 60 days (or such earlier date as the Release Agreement provides) following the date of your termination of employment. Such payments and benefits shall begin
to be paid or provided in the first regular payroll period beginning after the Release Agreement becomes binding on you; provided, however, that if the 60th day after termination occurs in the calendar year following the year of your date of termination, the severance
payments and benefits shall be paid or provided no earlier than January 1 of such subsequent calendar year (whether or not the Release Agreement is executed prior to such date). You must continue to comply with the covenants referenced in
Section 7 to continue to receive severance benefits. The severance payments and benefits shall constitute your sole remedy in connection with the termination of your employment in the event of a termination of your employment by the Company
without Cause or by you for Good Reason. 
 (f)        For purposes of this Agreement,
Cause shall mean (i) a material breach of any material term of this Agreement, (ii) a plea of guilty or nolo contendere to, or conviction of, a felony offense, (iii) repeated unexplained or unjustified absence, or refusals to carry
out the lawful directions of the Board or (iv) material breach of a fiduciary duty owed to the Company under this Agreement, provided that any action or inaction described by (i), (iii) or (iv), above, shall not be the basis of a
termination of your employment with the Company for “Cause” unless the Company provided you with at least 20 days advance written notice specifying in reasonable detail the conduct in need of being cured and such conduct was not cured
within the notice period or prior to termination. 

  
 - 3 -

 (g)        For purposes of this Agreement, a Change
of Control shall mean the occurrence of any of the following events: (i) a change in the composition of the Board over a period of thirty-six consecutive months or less such that a majority of the members of the Board ceases to be comprised of
individuals who are Continuing Members; for such purpose, a “Continuing Member” shall mean an individual who is a member of the Board on the date of this Agreement and any successor of a Continuing Member who is elected to the Board or
nominated for election by action of a majority of Continuing Members then serving on the Board; (ii) any merger or consolidation that results in the voting securities of the Company outstanding immediately prior thereto representing (either by
remaining outstanding or by being converted into voting securities of the surviving or acquiring entity) less than 60% of the combined voting power of the voting securities of the Company or such surviving or acquiring entity outstanding immediately
after such merger or consolidation; (iii) any sale of all or substantially all of the assets of the Company; (iv) the complete liquidation or dissolution of the Company; or (v) the acquisition of “beneficial ownership” (as
defined in Rule 13d-3 under the Exchange Act) of securities of the Company representing 50% or more of the combined voting power of the Company’s then outstanding securities (other than through a merger or consolidation or an acquisition of
securities directly from the Company) by any “person,” as such term is used in Sections 13(d) and 14(d) of the Exchange Act, other than the Company, any trustee or other fiduciary holding securities under an employee benefit plan of the
Company or any corporation owned directly or indirectly by the stockholders of the Company in substantially the same proportion as their ownership of stock of the Company; provided however that, where applied to compensation subject to
Section 409A of the Internal Revenue Code and the guidance issued thereunder (“Section 409A”), any acceleration of or change in payment shall only apply (if required by Section 409A) if the Change of Control is also a change in
control event described in Treasury Regulation 1.409A-3(i)(5). 

(h)        For purposes of this Agreement, Good Reason shall mean any action
on the part of the Company not consented to by you in writing having the following effect or effects: (i) a material reduction in your base salary; (ii) a material diminution in your duties, responsibilities or authority as set forth in
Section 1 of this Agreement or (iii) the Company’s requiring you to perform your ongoing and regular services at a location more than 50 miles from the location you are then performing your ongoing and regular services. You must
(A) give notice to the Company of your intention to resign for Good Reason within 90 days after the occurrence of the event (or series of events) that you assert entitle you to resign for Good Reason, (B) state in that notice the condition
that you consider to provide you with Good Reason to resign, (C) provide the Company with at least 30 days after you deliver your notice to cure the condition and (D) if the condition is not cured, resign for Good Reason on or prior to the
60th day after you deliver your notice. 

  
 - 4 -

	7.	Invention, Non-Disclosure and Non-Competition Agreement. You have previously executed an Invention, Non-Disclosure and Non-Competition Agreement with the
Company and hereby ratify and confirm your ongoing obligations under such agreement. 

  

	8.	Company Policies and Procedures. As an employee of the Company, you will be required to comply with all Company policies and procedures. Violations of the
Company’s policies may lead to immediate termination of your employment. Further, the Company’s premises, including all workspaces, furniture, documents and other tangible materials, and all information technology resources of the Company
(including computers, data and other electronic files, and all internet and e-mail) are subject to oversight and inspection by the Company at any time. Company employees should have no expectation of privacy with regard to any Company premises,
materials, resources or information. 

  

	9.	Other Agreements and Governing Law. You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing
you from continuing in employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this Agreement. Please note that this Agreement supersedes any and all prior or contemporaneous
agreements, discussions and/or understandings, whether written or oral, relating to the subject matter of this Agreement or your employment with the Company, including without limitation the Prior Agreement which shall terminate as of the Effective
Date. The resolution of any disputes under this Agreement will be governed by Massachusetts law. 

  

	10.	Compliance with Section 409A. Subject to the provisions in this Section 10, any severance payments or benefits under this Agreement (including
under Section 6 hereof) shall begin only upon the date of your “separation from service” (determined as set forth below) which occurs on or after the date of termination of your employment. The following rules shall apply with respect
to distribution of the payments and benefits, if any, to be provided to you under this Agreement: 

(a)        It is intended that each installment of the severance payments and benefits provided
under this Agreement shall be treated as a separate “payment” for purposes of Section 409A. Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent
specifically permitted or required by Section 409A. 
 (b)        If, as of the date
of your “separation from service” from the Company, you are not a “specified employee” (within the meaning of Section 409A), then each installment of the severance payments and benefits shall be made on the dates and terms
set forth in this Agreement. 

  
 - 5 -

 (c)        If, as of the date of your
“separation from service” from the Company, you are a “specified employee” (within the meaning of Section 409A), then: 
 (i) Each installment of the severance payments and benefits due under this Agreement that, in accordance with the dates and terms set forth herein, will in all circumstances, regardless of when the
separation from service occurs, be paid within the Short-Term Deferral Period (as hereinafter defined) shall be treated as a short-term deferral within the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible
under Section 409A. For purposes of this Agreement, the “Short-Term Deferral Period” means the period ending on the later of the fifteenth day of the third month following the end of your tax year in which the separation from service
occurs and the fifteenth day of the third month following the end of the Company’s tax year in which the separation from service occurs; and 
 (ii) Each installment of the severance payments and benefits due under this Agreement that is not described in Section 10(c)(i) above and that would, absent this subsection, be paid within the
six-month period following your “separation from service” from the Company shall not be paid until the date that is six months and one day after such separation from service (or, if earlier, your death), with any such installments that are
required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six months and one day following your separation from service and any subsequent installments, if any, being paid in accordance with the
dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply to any installment of severance payments and benefits if and to the maximum extent that such installment is deemed to
be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any
installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be paid no later than the last day of your second taxable year following your taxable year in which the separation from service occurs.

 (d)        The determination of whether and when your separation from service from the
Company has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation Section 1.409A-1(h). Solely for purposes of this Section 10(d), “Company” shall include all persons
with whom the Company would be considered a single employer under Section 414(b) and 414(c) of the Code. 

(e)        All reimbursements and in-kind benefits provided under this Agreement shall be made or
provided in accordance with the requirements of Section 409A to the extent that such reimbursements or in-kind benefits are subject to Section 409A, including, where applicable, the requirements that (i) any reimbursement is for
expenses incurred during your lifetime (or during a shorter period of time specified in this Agreement), (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the

  
 - 6 -

 
expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an eligible expense will be made on or before the last day of the calendar year following the year
in which the expense is incurred and (iv) the right to reimbursement is not subject to set off or liquidation or exchange for any other benefit. 
 (f)        Notwithstanding anything herein to the contrary, the Company shall have no liability to you or to any other person if the payments and benefits provided
hereunder that are intended to be exempt from or compliant with Section 409A are not so exempt or compliant. 
  

	11.	Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns,
including any corporation with which or into which the Company may be merged or which may succeed to its assets or business; provided, however, that your obligations to the Company are personal and shall not be assigned by you.

  

	12.	Acknowledgment. You state and represent that you have had an opportunity to fully discuss and review the terms of this Agreement with an attorney. You
further state and represent that you have carefully read this Agreement, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof, and sign your name of your own free act. 

 

	13.	Coordination With Certain Tax Rules. 

 (a)        In the event that the Company undergoes a Change in Ownership or Control (as defined below), the Company shall not be obligated to provide to the
Participant a portion of any Contingent Compensation Payments (as defined below) that the Participant would otherwise be entitled to receive to the extent necessary to eliminate any Excess Parachute Payments (as defined below) for the Participant.
For purposes of this Section 1.03, the Contingent Compensation Payments so eliminated shall be referred to as the “Eliminated Payments” and the aggregate amount (determined in accordance with Treasury Regulation Section 1.280G-1,
Q/A-30 or any successor provision) of the Contingent Compensation Payments so eliminated shall be referred to as the “Eliminated Amount.” Notwithstanding any other provision of this Plan, if the Eliminated Amount for the Participant equals
or exceeds the sum of (i) the Income Tax Payable on the Eliminated Amount (as defined below), plus (ii)the Excise Tax Payable on Excess Parachute Payments (as defined below), no portion of any Contingent Compensation Payments shall be
eliminated for the Participant. 
 (b)        For purposes of this Section 13, the
following terms shall have the following respective meanings: 
 (i)        “Change
in Ownership or Control” shall mean a change in the ownership or effective control of the Company or in the ownership of a substantial portion of the assets of the Company determined in accordance with Section 280G(b)(2) of the Code.

  
 - 7 -

 (ii)        “Contingent Compensation
Payments” shall mean any payment (or benefit) in the nature of compensation that is made or made available (under this Plan or otherwise) to a “disqualified individual” (as defined in Section 280G(c) of the Code) and that is
contingent (within the meaning of Section 280G (b) (2) (A) (i) of the Code) on a Change in Ownership or Control of the Company. 
 (iii)        “Excess Parachute Payments” shall mean “excess parachute payments” as defined in Section 280G(b)(1) of the Code before taking
into account the Eliminated Amount, if otherwise applicable. 
 (iv)        “Income
Tax Payable on the Eliminated Amount” shall mean the Eliminated Amount (determined without regard to whether any Contingent Compensation Payments are actually eliminated) multiplied by the highest combined marginal federal, state and local
income tax rate in effect for the taxable year, taking into account the phase-out of itemized deductions and the federal Medicare tax. 
 (v)        “Excise Tax Payable on Excess Parachute Payments” shall mean the tax imposed by Section 4999(a) of the Code on Excess Parachute Payments.

 (c)        Within 45 days after each date on which the Participant first becomes
entitled to receive (whether or not then due) payments or benefits relating to a Change in Ownership or Control, the Company, at its expense, shall engage a nationally recognized law firm or a nationally recognized accounting firm, which may be the
regular law firm or accounting firm of the Company (the “280G Firm”), to determine (i) which of such payments and benefits constitute Contingent Compensation Payments, (ii) the Eliminated Amount and (iii) the Eliminated
Payments. To identify the Eliminated Payments, the 280G Firm shall determine the “Contingent Compensation Payment Ratio” (as defined below) for each Contingent Compensation Payment and then reduce the Contingent Compensation Payments in
order beginning with the Contingent Compensation Payments with the highest Contingent Compensation Payment Ratio. For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio, such Contingent Compensation Payments shall
be reduced based on the time of payment of such Contingent Compensation Payments, with amounts having later payment dates being reduced first. For Contingent Compensation Payments with the same Contingent Compensation Payment Ratio and the same time
of payment, such Contingent Compensation Payments shall be reduced on a pro rata basis (but not below zero) prior to reducing Contingent Compensation Payments with a lower Contingent Compensation Payment Ratio. The term “Contingent Compensation
Payment Ratio” shall mean a fraction, the numerator of which is the value of the applicable Contingent Compensation Payment that must be taken into account at the change in 

  
 - 8 -

 
control date for purposes of Section 280G of the Code, and the denominator of which is the present value at the change in control date of the actual amount to be received in respect of the
applicable payment (e.g., in the case of equity grants, the denominator shall be determined by reference to the fair market value of the equity at the relevant dates and not in accordance with the methodology for accelerated payments set forth
in Treasury Regulation Section 1.280G-1Q/A 24(b) or (c)). 
 (d)        Within 30
days after each date on which the Participant first becomes entitled to receive (whether or not then due) payments or benefits relating to such Change in Ownership or Control, the Company shall provide notice to the Participant with reasonable
detail of (i) which payments and benefits constitute Contingent Compensation Payments, (ii) the Eliminated Amount and (iii) the Eliminated Payments. 
 (e)        In the event of any underpayment or overpayment hereunder, as determined by the 280G Firm, the amount of such underpayment or overpayment shall within 30
days of such determination be paid to the Participant or refunded to the Company, as the case may be, with interest at the applicable federal rate provided for in Section 7872(f)(2) of the Code. 

 

	14.	Miscellaneous. 

(a)        No delay or omission by the Company in exercising any right under this Agreement shall
operate as a waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion. 

(b)        The captions of the sections of this Agreement are for convenience of reference only
and in no way define, limit or affect the scope or substance of any section of this Agreement. 

(c)        In case any provision of this Agreement shall be invalid, illegal or otherwise
unenforceable, the validity, legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby. 

  
 - 9 -

 If you are in agreement with, and agree to, the terms under which you will continue to be employed by the
Company, please sign the enclosed duplicate of this Agreement in the space provided below and return it to me. 
  

			
	Very truly yours,
		
	By:	 	 /s/ Sudhir Agrawal

	Name:	 	Sudhir Agrawal
	Title:	 	Chief Executive Officer

 The foregoing correctly sets forth the terms of my employment with Idera Pharmaceuticals, Inc. I am not relying on
any representations other than as set forth above. 
  

											
	 Louis J. Arcudi
	 		 		 		 	Date: 12-2-11                      	 	
	Louis J. Arcudi	 		 		 		 		 	

  
 - 10 -EX-10.18

 Exhibit 10.18 
 Director Compensation Program 
 Under our director compensation program, we
pay our non-employee directors retainers in cash. Each non-employee director receives a cash retainer for service on the board of directors and for service on each committee on which the director is a member. These fees are payable quarterly in
arrears and are as follows: 
 Cash Fees 
  

									
	 	  	Member
Annual Fee	 	  	Chairman
Annual Fee	 
	 Board of Directors
	  	$	35,000	  	  	$	60,000	  
	 Audit Committee
	  	$	7,000	  	  	$	15,000	  
	 Compensation Committee
	  	$	7,000	  	  	$	15,000	  
	 Nominating and Corporate Governance Committee
	  	$	3,500	  	  	$	7,500	  
	 Scientific Committee
	  	$	7,000	  	  	$	15,000	  

 The Lead Independent Director of the Board of Directors receives an annual fee of $17,500 for service as Lead Independent
Director in addition to any other fees such Lead Independent Director is entitled to for service on the Board of Directors. 
 Equity Fees

 Our director compensation program also includes a stock-for-fees policy, under which directors have the right to elect to
receive common stock in lieu of cash fees. The number of shares to be issued to participating directors is determined on a quarterly basis by dividing the cash fees to be issued in common stock by the fair market value of our common stock, which is
the closing price of our common stock, on the first business day of the quarter following the quarter in which the fees were earned. 
 Under our director compensation program, upon their initial election to the board of directors, new non-employee directors receive an option grant for 30,000 shares and all non-employee directors receive
an annual option grant for 20,000 shares. The annual grants are made on the date of the annual meeting of stockholders. These options vest quarterly over three years from the date of grant, subject to continued service as a director, and are granted
under our 2008 Stock Incentive Plan. These options are granted with exercise prices equal to the fair market value of our common stock, which is the closing price of our common stock, on the date of grant and become immediately exercisable in full
if there is a change in control of our company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]